DuRvalumab MEDI4730 with chEmotherapy as first line treAtment in advanced pleural Mesothelioma A phase 3 Randomised trial (DREAM3R) (PrE0506)(PSCI#20-123)
Participants may receive the medication Durvalumab in addition to standard of care medications or standard of care medications alone for treatment of Mesothelioma.
This is a randomized study. We do not know which treatment is best for participants. Randomization means that participants will be put into two different groups for treatment. One group is the Experimental Group (standard chemotherapy with durvalumab). The other group is the Control Group (either standard chemotherapy, or immunotherapy with ipilimumab and nivolumab). Before you are randomized your Study Doctor will choose if you will receive standard chemotherapy or immunotherapy with ipilimumab and nivolumab if you are randomized to the Control Group. The results of each group are compared to see if one is better.
post menopausal or negative pregnancy test
greater than 66 pounds in weight
life expectancy of at least 12 weeks
metastasized to the brain